American Association for the Advancement of Science, Science Translational Medicine, 624(13), 2021
DOI: 10.1126/scitranslmed.abg8116
Full text: Unavailable
IMA-1 targets the ALOX12-ACC1 interaction to both prevent and treat NASH without inducing hyperlipidemia.